Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ARHGEF12
REST API REST API
Homo sapiens
ARHGEF12 is differentially expressed in 323 experiments: 145 organism parts: heart, liver, ... (143 more);, 241 disease states: normal, glioblastoma, ... (239 more);, 121 cell types 404 cell lines 42 compound treatments and 88 other conditions.
Synonyms LARG, KIAA0382
Orthologs Arhgef12 (Mus musculus)   ARHGEF12 (Bos taurus)   Arhgef12 (Rattus norvegicus)   ARHGEF12 (Gallus gallus)   ARHGEF12 (1 of 2) (Danio rerio)   ARHGEF12 (2 of 2) (Danio rerio)   RhoGEF2 (Drosophila melanogaster)   arhgef12 (Xenopus laevis)   ARHGEF12 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, protein binding, apoptosis, cytoplasm, intracellular, membrane, G-protein coupled receptor protein signaling pathway, G-protein-coupled receptor binding, regulation of Rho protein signal transduction, guanyl-nucleotide exchange factor activity, GTPase activator activity, axon guidance, small GTPase mediated signal transduction, regulation of small GTPase mediated signal transduction, Rho guanyl-nucleotide exchange factor activity, induction of apoptosis by extracellular signals, nerve growth factor receptor signaling pathway, intracellular signal transduction
InterPro Term Regulat_G_prot_signal-like, PDZ/DHR/GLGF, Pleckstrin_homology, DH-domain
UniProt Accession Q9NZN5, B4E2K6, E9PMR6
Gene-Disease Assocation LEUKEMIA, ACUTE MYELOID; AML
Search EB-eye ENSG00000196914
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-22541, E-GEOD-6573, E-GEOD-7224, ... (30 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-19397, ... (38 experiments)

Factor Value U/D Experiments
HL-60
3
E-GEOD-5258, E-MTAB-37, E-GEOD-24147
MCF-7
3
E-GEOD-20081, E-GEOD-19639, E-GEOD-3529
BT20
2
E-MTAB-37, E-MTAB-62
CCRFCEM
2
E-GEOD-24147, E-MTAB-37
HCC38
2
E-MTAB-37, E-MTAB-62
MDA468
2
E-MTAB-62, E-MEXP-440
398 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-MEXP-120, E-MEXP-750, ... (61 experiments)

Factor Value U/D Experiments
adipocyte
2
E-MTAB-25, E-AFMX-5
human foreskin fibroblast
2
E-GEOD-18265, E-GEOD-18147
mononuclear cell
2
E-MEXP-66, E-GEOD-6053
hematopoietic stem cell
2
E-MEXP-872, E-MEXP-1403
macrophage
2
E-GEOD-22373, E-GEOD-360
1
2
E-TABM-145, E-TABM-130
115 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-TABM-15, ... (65 experiments)

Factor Value U/D Experiments
glioblastoma
1
5
E-GEOD-4290, E-GEOD-6014, E-MTAB-62, E-GEOD-4412, E-MTAB-37, ... (6 experiments)
colon carcinoma
3
E-MTAB-37, E-MTAB-62, E-GEOD-3726
lung adenocarcinoma
3
E-MTAB-62, E-MTAB-37, E-MEXP-231
colorectal adenocarcinoma
2
E-AFMX-5, E-MTAB-62
lung carcinoma
2
E-GEOD-6014, E-MTAB-37
acute quadriplegic myopathy
2
E-MTAB-62, E-GEOD-3307
235 more value(s).


Compound treatment

studied in E-GEOD-7400, E-TABM-782, E-GEOD-5824, E-GEOD-3720, E-TABM-868, ... (29 experiments)

Factor Value U/D Experiments
lipopolysaccharide
3
E-TABM-868, E-MEXP-1958, E-GEOD-3720
none
5
7
E-GEOD-412, E-GEOD-5824, E-TABM-868, E-MEXP-1958, E-GEOD-5099, ... (12 experiments)
rapamycin
1
E-GEOD-5824
control for EGF
1
E-GEOD-6462
vanadium pentoxide
1
E-GEOD-5339
5-aza-2'-deoxycytidine + trichostatin A
2
1
E-MEXP-1269
36 more value(s).


Age at diagnosis

studied in E-GEOD-4922

Factor Value U/D Experiments
32 years
1
1
E-GEOD-4922


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-GEOD-22513, ... (12 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-1638, E-GEOD-20033, E-MEXP-2359, ... (9 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-3325, E-GEOD-22541, E-GEOD-22148, ... (8 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MTAB-73, E-GEOD-4025, E-MEXP-1482, ... (10 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-22056, E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, ... (12 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-MEXP-2657, E-GEOD-12773, E-TABM-127, ... (12 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

immunoprecipitated protein
studied in E-GEOD-21918

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-MEXP-2069, E-GEOD-16363, ... (36 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, ... (6 experiments)

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-22056, E-GEOD-12662

Ki67 ihc
studied in E-GEOD-21653

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-1082

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-19703, E-GEOD-21750, E-MEXP-1412, E-GEOD-1657, ... (8 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-19069, E-GEOD-2466, E-GEOD-7307, E-GEOD-1295

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

tissue (organ)
studied in E-GEOD-22601

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-22152, E-GEOD-16837, E-GEOD-19246, E-GEOD-19815, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Ttf
studied in E-GEOD-21521

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-3494, E-GEOD-22541, E-GEOD-1561, ... (6 experiments)

Vehicle
studied in E-GEOD-5258

Processing time: 0.511 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM